Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.

Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P. · 2023

Read Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. by Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10322706.txt.

Description

Kim and a large team reported a new drug in 2023 that blocks KRAS, a protein often changed in cancer. KRAS acts like a switch that tells cells to grow. When the switch sticks on, tumours can form. Past drugs could block just one form of the switch, called G12C.

The new drug from Kim binds KRAS when the switch is off, and it spares two close kin proteins. It stopped the switch from turning on in tests on many changed forms. Growth slowed only in cancer cells that held a changed KRAS. In mice, the drug shrank tumours with no loss of body weight.

Catalog record

CREATORKim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10322706

Browse the full library · About the Tower of Babel